Vulvar intraepithelial neoplasia

Vulvar intraepithelial neoplasia (VIN) is a rare but premalig-nant condition. VIN has two aetiological pathways: a human papillomavirus (HPV)-dependent pathway, which is a vulvar high-grade squamous intraepithelial lesion (HSIL), and an HPV-independent pathway, called differentiated VIN (d-VIN), ass...

Full description

Saved in:
Bibliographic Details
Published inUgeskrift for læger Vol. 180; no. 20
Main Authors Østergård, Signe, Vorbeck, Christina Steen, Meinert, Mette
Format Journal Article
LanguageDanish
Published Denmark 14.05.2018
Subjects
Antineoplastic Agents - therapeutic use
Carcinoma in Situ - classification
Carcinoma in Situ - drug therapy
Carcinoma in Situ - pathology
Carcinoma in Situ - virology
Female
Humans
Imiquimod - therapeutic use
Immunocompromised Host
Papillomaviridae - isolation & purification
Papillomavirus Infections - complications
Papillomavirus Vaccines - therapeutic use
Precancerous Conditions
Vulvar Neoplasms - classification
Vulvar Neoplasms - drug therapy
Vulvar Neoplasms - pathology
Vulvar Neoplasms - virology
Online AccessGet more information

Cover

More Information
Summary:Vulvar intraepithelial neoplasia (VIN) is a rare but premalig-nant condition. VIN has two aetiological pathways: a human papillomavirus (HPV)-dependent pathway, which is a vulvar high-grade squamous intraepithelial lesion (HSIL), and an HPV-independent pathway, called differentiated VIN (d-VIN), associated with lichen sclerosus. d-VIN is more aggressive than vulvar HSIL. In case of symptoms, a biopsy should be performed. The recurrence risk is high: 25-50% regardless of treatment type. We recommend treatment with imiquimod as first choice to avoid mutilating surgery. Particular attention must be payed to immunosuppressed patients with VIN. HPV-vaccine can be discussed with patients with vulvar HSIL.
ISSN:1603-6824